申请人:Ono Pharmaceutical Co., Ltd.
公开号:US08962868B2
公开(公告)日:2015-02-24
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
由于一种化合物的通式表示为(I)(其中每个基团的定义如规范所述),它的盐,溶剂化合物或前药具有强大而持久的降低眼压的活性,并且进一步没有眼部刺激性的副作用(充血,角膜混浊等),眼房水蛋白升高等,具有高度的安全性,并且可以成为预防和/或治疗青光眼等的优秀药物。